Twelve-year follow-up study of hepatitis B immunization of Senegalese infants.
J Hepatol
; 21(2): 250-4, 1994 Aug.
Article
in En
| MEDLINE
| ID: mdl-7989718
ABSTRACT
Numerous studies have documented the efficacy and safety of plasma-derived and recombinant hepatitis B vaccines. However, little is known about the long-term protection of hepatitis B vaccine, when anti-HBs declines to low or undetectable levels. This study reports results from a 9-12-year period follow up of infants immunized against hepatitis B in Senegal. At the end of the follow-up period anti-HBs were detected in 81% of children who received a booster dose at school age and in 68% of those who did not. HBsAg was detected in 19% of infants from the control group compared to only 2% of immunized infants, corresponding to a protective efficacy of 88%. The results show that long-term protection against HBsAg carriage of hepatitis B vaccination is very high and that a booster dose at school age does not significantly increase this protection.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hepatitis B Vaccines
/
Hepatitis B
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Child
/
Child, preschool
/
Humans
/
Infant
/
Newborn
Country/Region as subject:
Africa
Language:
En
Journal:
J Hepatol
Journal subject:
GASTROENTEROLOGIA
Year:
1994
Document type:
Article